Treprostinil — Active Pharmaceutical Ingredient

Treprostinil is an active pharmaceutical ingredient found in 4 FDA-approved drug products. Forms: INJECTABLE, SOLUTION, POWDER, TABLET, EXTENDED RELEASE. Routes: INTRAVENOUS, SUBCUTANEOUS, INHALATION, ORAL.

This content is for informational purposes only. Always consult a healthcare professional.

Treprostinil (4 brand names, 4 dosage forms, 3 routes)

Available dosage forms: INJECTABLE, SOLUTION, POWDER, TABLET, EXTENDED RELEASE.

Routes of administration: INTRAVENOUS, SUBCUTANEOUS, INHALATION, ORAL.

Brand Names

  • REMODULIN
  • TREPROSTINIL
  • TYVASO
  • TYVASO DPI

Contraindications

None.

Adverse Reactions

The following potential adverse reactions are described in Warnings and Precautions (5): -Decrease in systemic blood pressure [see Warnings and Precautions (5.1)]. -Bleeding [see Warnings and Precautions (5.2)].

Mechanism of Action

Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Overdosage

In general, symptoms of overdose with Tyvaso include flushing, headache, hypotension, nausea, vomiting, and diarrhea. Provide general supportive care until the symptoms of overdose have resolved.

⚠ Caution
Medical Disclaimer: This information is for educational purposes only. Always consult a healthcare professional before taking any medication.